HNF‑4α promotes multidrug resistance of gastric cancer cells through the modulation of cell apoptosis

Ma,Yubo; Wei,Xufu; Wu,Zhongjun

doi:10.3892/ol.2017.7095

HNF‑4α promotes multidrug resistance of gastric cancer cells through the modulation of cell apoptosis

Authors:
- Yubo Ma
- Xufu Wei
- Zhongjun Wu
View Affiliations

Affiliations: The First Clinical College, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Hepatobiliary Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: September 28, 2017 https://doi.org/10.3892/ol.2017.7095
Pages: 6477-6484
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) typically leads to treatment failure, and is associated with disease progression of gastric cancer (GC). In the present study, a total of 15 aberrantly activated transcription factors (TFs) were detected in chemo‑resistant GC cells using a TF Activation Profiling Plate Array. Among these TFs, hepatocyte nuclear factor (HNF)‑4α was significantly upregulated in multidrug‑resistant GC cells (P=0.019). The overexpression of HNF‑4α was able to cause resistance to multiple chemotherapeutics, whereas inhibition of HNF‑4α appeared to reverse cancer cell resistance. Further studies demonstrated that HNF‑4α had no clear influence on drug transportation; however, inhibition of drug‑induced cell apoptosis occurred as B‑cell lymphoma 2 (Bcl‑2) expression increased in GC cells. Additionally, immunohistochemistry demonstrated that HNF‑4α was overexpressed in human GC tissues, and associated with tumor stage and lymph node metastasis. In conclusion, the results of the present study indicate the involvement of TFs in MDR in GC, and suggest that HNF‑4α may enhance MDR in GC by regulating cell apoptosis and Bcl‑2 expression.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Fodale V, Pierobon M, Liotta L and Petricoin E: Mechanism of cell adaptation: When and how do cancer cells develop chemoresistance? Cancer J. 17:89–95. 2011. View Article : Google Scholar : PubMed/NCBI
3	Noguchi K, Katayama K and Sugimoto Y: Human ABC transporter ABCG2/BCRP expression in chemoresistance: Basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med. 7:53–64. 2014.PubMed/NCBI
4	Elkholi R, Renault TT, Serasinghe MN and Chipuk JE: Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab. 2:162014. View Article : Google Scholar : PubMed/NCBI
5	Pflaum J, Schlosser S and Müller M: p53 family and cellular stress responses in cancer. Front Oncol. 4:2852014. View Article : Google Scholar : PubMed/NCBI
6	Amelio I and Melino G: The p53 family and the hypoxia-inducible factors (HIFs): Determinants of cancer progression. Trends Biochem Sci. 40:425–434. 2015. View Article : Google Scholar : PubMed/NCBI
7	Ozaki T, Nakamura M and Shimozato O: Novel implications of DNA damage response in drug resistance of malignant cancers obtained from the functional interaction between p53 family and RUNX2. Biomolecules. 5:2854–2876. 2015. View Article : Google Scholar : PubMed/NCBI
8	Endo F, Nishizuka SS, Kume K, Ishida K, Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K and Wakabayashi G: A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines. PLoS One. 9:e901552014. View Article : Google Scholar : PubMed/NCBI
9	Prabhu L, Mundade R, Korc M, Loehrer PJ and Lu T: Critical role of NF-κB in pancreatic cancer. Oncotarget. 5:10969–10975. 2014. View Article : Google Scholar : PubMed/NCBI
10	Li F, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: NF-κB in cancer therapy. Arch Toxicol. 89:711–731. 2015. View Article : Google Scholar : PubMed/NCBI
11	Hong L, Qiao T, Han Y, Han S, Zhang X, Lin T, Gao J, Zhao P, Chen Z and Fan D: ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2. Biochem Cell Biol. 84:199–206. 2006. View Article : Google Scholar : PubMed/NCBI
12	Zhao L, Pan Y, Gang Y, Wang H, Jin H, Tie J, Xia L, Zhang Y, He L, Yao L, et al: Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library. J Biol Chem. 284:26273–26285. 2009. View Article : Google Scholar : PubMed/NCBI
13	Su L, Liu X, Chai N, Lv L, Wang R, Li X, Nie Y, Shi Y and Fan D: The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer. BMC Cancer. 14:3782014. View Article : Google Scholar : PubMed/NCBI
14	Liu L, Sun L, Zhang H, Li Z, Ning X, Shi Y, Guo C, Han S, Wu K and Fan D: Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance. Int J Cancer. 124:1707–1715. 2009. View Article : Google Scholar : PubMed/NCBI
15	Liu L, Zhang H, Sun L, Gao Y, Jin H, Liang S, Wang Y, Dong M, Shi Y, Li Z, et al: ERK/MAPK activation involves hypoxia-induced MGr1-Ag/37LRP expression and contributes to apoptosis resistance in gastric cancer. Int J Cancer. 127:820–829. 2010.PubMed/NCBI
16	Chen F, Zhuang M, Zhong C, Peng J, Wang X, Li J, Chen Z and Huang Y: Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway. Oncol Rep. 33:457–463. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zhou W, Fu XQ, Zhang LL, Zhang J, Huang X, Lu XH, Shen L, Liu BN, Liu J, Luo HS, et al: The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells. Cell Death Dis. 4:e8472013. View Article : Google Scholar : PubMed/NCBI
18	Zhi X, Tao J, Xiang G, Cao H, Liu Z, Yang K, Lv C and Ni S: APRIL induces cisplatin resistance in gastric cancer cells via activation of the NF-κB pathway. Cell Physiol Biochem. 35:571–585. 2015. View Article : Google Scholar : PubMed/NCBI
19	Chen PM, Cheng YW, Wu TC, Chen CY and Lee H: MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway. Free Radic Biol Med. 79:127–137. 2015. View Article : Google Scholar : PubMed/NCBI
20	Hayashi Y, Wang W, Ninomiya T, Nagano H, Ohta K and Itoh H: Liver enriched transcription factors and differentiation of hepatocellular carcinoma. Mol Pathol. 52:19–24. 1999. View Article : Google Scholar : PubMed/NCBI
21	Liu H, Lou G, Li C, Wang X, Cederbaum AI, Gan L and Xie B: HBx inhibits CYP2E1 gene expression via downregulating HNF4α in human hepatoma cells. PLoS One. 9:e1079132014. View Article : Google Scholar : PubMed/NCBI
22	Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, et al: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 513:110–114. 2014. View Article : Google Scholar : PubMed/NCBI
23	Schwartz B, Algamas-Dimantov A, Hertz R, Nataf J, Kerman A, Peri I and Bar-Tana J: Inhibition of colorectal cancer by targeting hepatocyte nuclear factor-4alpha. Int J Cancer. 124:1081–1089. 2009. View Article : Google Scholar : PubMed/NCBI
24	Kojima K, Kishimoto T, Nagai Y, Tanizawa T, Nakatani Y, Miyazaki M and Ishikura H: The expression of hepatocyte nuclear factor-4alpha, a developmental regulator of visceral endoderm, correlates with the intestinal phenotype of gastric adenocarcinomas. Pathology. 38:548–554. 2006. View Article : Google Scholar : PubMed/NCBI
25	Supriatna Y, Kishimoto T, Furuya M, Tochigi N, Ishiguro H, Tosh D and Ishikura H: Expression of liver-enriched nuclear factors and their isoforms in alpha-fetoprotein-producing gastric carcinoma cells. Exp Mol Pathol. 82:316–321. 2007. View Article : Google Scholar : PubMed/NCBI
26	Algamas-Dimantov A, Yehuda-Shnaidman E, Peri I and Schwartz B: Epigenetic control of HNF-4α in colon carcinoma cells affects MUC4 expression and malignancy. Cell Oncol (Dordr). 36:155–167. 2013. View Article : Google Scholar : PubMed/NCBI
27	Nikolaidou-Neokosmidou V, Zannis VI and Kardassis D: Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathway. Biochem J. 398:439–450. 2006. View Article : Google Scholar : PubMed/NCBI
28	Roth U, Curth K, Unterman TG and Kietzmann T: The transcription factors HIF-1 and HNF-4 and the coactivator p300 are involved in insulin-regulated glucokinase gene expression via the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem. 279:2623–2631. 2004. View Article : Google Scholar : PubMed/NCBI
29	Zhang W, Tsuchiya T and Yasukochi Y: Transitional change in interaction between HIF-1 and HNF-4 in response to hypoxia. J Hum Genet. 44:293–299. 1999. View Article : Google Scholar : PubMed/NCBI